Opinion of the Transparency Council – leflunomidum

At its meeting on 11 July 2022 the Transparency Council adopted opinion No. 109/2022 on reimbursement of medicines containing the active substance leflunomidum for indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics.